Controlling the controls: On the importance of validated negative control ASOs
Molecular Therapy Nucleic Acids · 2026-12 · 37 (4) · 103136
DOI: 10.1016/j.omtn.2026.103136 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy Nucleic Acids, 2026-12. Verfasst von János Farkas und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cellular, Computational and Integrative Biology - CIBIO, University of Trento, Trento, Italy. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: EU Framework Programme for Research and Innovation Marie Skłodowska-Curie Actions.
Abstract (Originalsprache)
Antisense oligonucleotide (ASO) therapeutics have moved from a niche modality to a validated class of drugs, with more than a dozen agents now approved and many more advancing through preclinical and clinical pipelines. Each of these programs depends on a deceptively simple ingredient: a negative control ASO that separates the sequence-specific activity of a candidate oligonucleotide from the effects of its chemistry and delivery. In practice, researchers usually improvise a scrambled or mismatched control for each new candidate, an approach that is rarely well characterized and can involve unpredictable biological activity.
Autor:innen und Institutionen
- Department of Cellular, Computational and Integrative Biology - CIBIO, University of Trento, Trento, Italy.
Förderung
- EU Framework Programme for Research and Innovation Marie Skłodowska-Curie Actions
Zitieren
APA
Farkas, J., & Denti, M. A. (2026). Controlling the controls: On the importance of validated negative control ASOs. Molecular Therapy Nucleic Acids, 37(4), 103136. https://doi.org/10.1016/j.omtn.2026.103136
Vancouver
Farkas J, Denti MA. Controlling the controls: On the importance of validated negative control ASOs. Molecular Therapy Nucleic Acids. 2026;37(4):103136. doi:10.1016/j.omtn.2026.103136
BibTeX
@article{Farkas2026,
author = {Farkas, János and Denti, Michela A},
title = {Controlling the controls: On the importance of validated negative control ASOs},
journal = {Molecular Therapy Nucleic Acids},
year = {2026},
volume = {37},
number = {4},
pages = {103136},
doi = {10.1016/j.omtn.2026.103136}
}
EUVIMED